IP Library › Granted Patent US 7,115,712
Granted Patent B1
US 7,115,712 · App. 09/725,324 · Granted Oct 3, 2006

Cytokine polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,712
App. No.
09/725,324
Granted
Oct 3, 2006
Kind
B1
Abstract

New cytokine polypeptides, and nucleic acids encoding them, are provided. Compositions including these polypeptides and nucleic acids, recombinant cells comprising said polypeptides and nucleic acids, methods of making the polypeptides and nucleic acid, antibodies to the polypeptides, and methods of using the polypeptides and nucleic acids are provided. Integrated systems comprising the sequences of the nucleic acids or polypeptides are also provided.

Claims (12)

1. A recombinant polypeptide, wherein the recombinant polypeptide induces proliferation of T cells in the presence of a mature polypeptide region of a wild-type p35 polypeptide subunit of human interleukin-12, and wherein the recombinant polypeptide comprises a sequence that is at least 95% identical to the full length of the mature polypeptide region of SEQ ID NO:8.

2. The recombinant polypeptide of claim 1 , wherein the recombinant polypeptide comprises a sequence that is at least 97% identical to the full length of the mature polypeptide region of SEQ ID NO:8.

3. The recombinant polypeptide of claim 2 , wherein the recombinant polypeptide comprises the mature polypeptide region of SEQ ID NO:8.

4. A composition comprising the recombinant polypeptide of claim 1 and a carrier.

5. The composition of claim 4 , further comprising a mature polypeptide region of a wild-type p35 polypeptide subunit of human interleukin-12.

6. The composition of claim 4 , wherein the carrier is a pharmaceutically acceptable carrier.

7. A recombinant polypeptide, wherein the recombinant polypeptide induces proliferation of T cells in the presence of a wild-type p35 polypeptide subunit of human interleukin-12, and wherein the recombinant polypeptide comprises a sequence that is at least 95% identical to the full length of the sequence of SEQ ID NO:8.

8. The recombinant polypeptide of claim 7 , wherein the recombinant polypeptide comprises a sequence that is at least 97% identical to the full length of the sequence of SEQ ID NO:8.

9. The recombinant polypeptide of claim 8 , wherein the recombinant polypeptide comprises the sequence of SEQ ID NO:8.

10. A composition comprising the recombinant polypeptide of claim 7 and a carrier.

11. The composition of claim 10 , further comprising a wild-type p35 polypeptide subunit of human interleukin-12.

12. The composition of claim 11 , wherein the carrier is a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2009
From: MAXYGEN, INC.
To: PERSEID THERAPEUTICS LLC.
Reel/Frame 023649/0157 →
CONFIRMATORY LICENSE Recorded Oct 6, 2003
From: MAXYGEN INC.
To: NAVY SECRETARY OF THE UNITED STATES
Reel/Frame 014567/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2002
From: LEONG, STEVEN R.; PUNNONEN, JUHA
To: MAXYGEN, INC.
Reel/Frame 012465/0347 →